A Study to Explore the Effects of Azilsartan Compared to Telmisartan on Insulin Resistance of Patients With Essential Hypertension on Type 2 Diabetes Mellitus by HOMA-R

Exclusion Criteria

• •1. Grade III essential hypertension (i.e., sitting systolic blood pressure 180 mmHg or sitting diastolic blood pressure ≥ 110 mmHg), secondary hypertension, or malignant hypertension.
• •2. Grade II essential hypertension (i.e., sitting systolic blood pressure ≥ 160 mmHg or sitting diastolic blood pressure ≥ 100 mmHg) for which antihypertensive drug(s) are used
• •3. Use of oral antihypertensive medication within 2 weeks before the start of the treatment period Participants who are on any antihypertensive agent at the time of informed consent can be enrolled in the study only after 2-week washout following informed consent.
• •4. Use of RAS inhibitors or thiazolidines within 3 months before the start of the treatment period
• •5. Type 1 diabetes mellitus
• •6. Fasting blood glucose of \< 180 mg/dL and HOMA-R of ≤ 1.6 at the start of the treatment period (Week 0)
• •7. Receiving or requiring any of the following at the time of informed consent:
• •* Insulin, glucagon-like peptide-1 (GLP-1) receptor agonists, or other parenteral hypoglycemic agents
• •* Combination therapy with 3 or more oral hypoglycemic agents
• •8. Change of antidiabetic medication (including dosage change) within 3 months before the start of the treatment period
• •9. Having diagnosed/treated any of the following cardiovascular diseases within 3 months before the start of the treatment period:
• •* Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
• •* Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
• •* Advanced hypertensive retinopathy (retinal bleeding or oozing, papilloedema)
• •10. Having diagnosed/treated for any of the following cardiovascular diseases more than 3 months before the start of the treatment period, and is now still in unstable condition.
• •* Cardiac disease/condition: myocardial infarction, coronary revascularization procedure
• •* Cerebrovascular disease: cerebral infarction, cerebral haemorrhage, transient ischaemic attack
• •11. Past or current history of any of the following cardiovascular diseases.
• •* Cardiac valve stenosis
• •* Angina pectoris requiring medication
• •* Congestive cardiac failure requiring medication
• •* Arrhythmia requiring medication (e.g., paroxysmal atrial fibrillation, severe bradycardia, torsade de pointes, and ventricular fibrillation)
• •* Arteriosclerosis obliterans with intermittent claudication or other symptoms
• •12. Have severe ketosis, diabetic coma or precoma, severe infection, or serious trauma
• •13. Clinically evident renal disorder (e.g., eGFR \<30 mL/min/1.73 m2)
• •14. Markedly low bile secretion or severe hepatic disorder
• •15. History of hypersensitivity or allergy to azilsartan or telmisartan or to both.
• •16. Presence of hyperkalemia (potassium level ≥ 5.5 mEq/L on laboratory testing)
• •17. Currently participating in any other clinical study.
• •18. Pregnant women, women with possible pregnancy, or breast-feeding women.
• •19. Other participants who are inappropriate for participation in this study in the opinion of the principal investigator or investigator.